RedHill Biopharma (RDHL)
NASDAQ:RDHL
Want to see RDHL full AI Analyst Report?
Top Page
RedHill Biopharma
(NASDAQ:RDHL)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.00
▼(-16.75% Downside)
Action:Reiterated
Date:05/19/26
The score is weighed down primarily by weak financial performance—especially the sharp revenue decline, ongoing operating losses, and sustained cash burn—despite some balance-sheet repair (lower debt and positive equity in 2025). Technical indicators are mixed with only modest near-term momentum, and valuation cannot be meaningfully supported from the provided P/E and missing dividend yield.
Positive Factors
Opaganib: broad antiviral & oncology program
Opaganib is an oral, host-directed small molecule with demonstrated antiviral and oncology signals and active outreach to WHO and pharma partners for Ebola trials. This breadth and partner interest create durable strategic optionality—potential biodefense stockpiling, collaboration funding, and non-dilutive support if clinical signals persist.
Negative Factors
Severe revenue collapse
The dramatic drop in top-line erodes the commercial revenue base and undermines recurring cash generation capacity. Sustained revenue weakness reduces gross-profit buffer for R&D and commercialization, making future progress heavily dependent on pipeline successes, one-off licensing, or milestone payments rather than stable product sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Opaganib: broad antiviral & oncology program
Opaganib is an oral, host-directed small molecule with demonstrated antiviral and oncology signals and active outreach to WHO and pharma partners for Ebola trials. This breadth and partner interest create durable strategic optionality—potential biodefense stockpiling, collaboration funding, and non-dilutive support if clinical signals persist.
Read all positive factors
RedHill Biopharma (RDHL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.35M
Dividend YieldN/A
Average Volume (3M)1.98M
Price to Earnings (P/E)―
Beta (1Y)1.43
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees35
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-4.00
Shares Outstanding5,191,260
10 Day Avg. Volume104,605
30 Day Avg. Volume1,981,143
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.76
Price to Sales (P/S)11.38
P/FCF Ratio-0.34
Enterprise Value/Market Cap0.05
Enterprise Value/Revenue0.03
Enterprise Value/Gross Profit0.04
Enterprise Value/Ebitda-0.03
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)$50.60M
RedHill Biopharma Business Overview & Revenue Model
Company Description
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal diseases and cancer. The company operates primarily in the biopharmaceutical sector, with...
How the Company Makes Money
RedHill Biopharma makes money primarily through product-related revenues where it has commercial rights, plus any applicable collaboration-related economics tied to partnered products (e.g., licensing, distribution arrangements, and similar agreem...
RedHill Biopharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
35
Negative
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.55M | 286.00K | 8.04M | 6.53M | 61.80M | 85.76M |
| Gross Profit | 6.16M | 286.00K | 4.85M | 3.07M | 28.46M | 36.35M |
| EBITDA | -7.91M | -7.65M | -7.59M | 26.27M | -22.18M | -63.03M |
| Net Income | -9.31M | -429.00K | -8.27M | 23.92M | -71.67M | -97.74M |
Balance Sheet | ||||||
| Total Assets | 18.38M | 25.34M | 18.04M | 23.05M | 158.87M | 181.19M |
| Cash, Cash Equivalents and Short-Term Investments | 2.87M | 3.97M | 4.62M | 6.36M | 19.98M | 38.00M |
| Total Debt | 214.00K | 1.07M | 356.00K | 1.17M | 122.69M | 87.81M |
| Total Liabilities | 22.79M | 21.08M | 22.73M | 20.98M | 207.27M | 172.31M |
| Stockholders Equity | -4.41M | 4.27M | -4.68M | 2.07M | -48.40M | 8.88M |
Cash Flow | ||||||
| Free Cash Flow | -8.21M | -9.66M | -9.38M | -35.83M | -29.38M | -65.16M |
| Operating Cash Flow | -8.20M | -9.65M | -9.37M | -35.82M | -29.18M | -65.05M |
| Investing Cash Flow | -12.00K | 1.69M | -9.00K | 3.99K | 8.30M | -8.14M |
| Financing Cash Flow | 3.78M | 7.32M | 8.42M | 21.38M | 11.45M | 73.46M |
RedHill Biopharma Technical Analysis
Positive
1.20
Price Trends
0.93
Positive
0.99
Positive
1.19
Negative
Market Momentum
0.01
Negative
59.80
Neutral
56.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RDHL, the sentiment is Positive. The current price of 1.2 is above the 20-day moving average (MA) of 0.99, above the 50-day MA of 0.93, and above the 200-day MA of 1.19, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 59.80 is Neutral, neither overbought nor oversold. The STOCH value of 56.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RDHL.
RedHill Biopharma Risk Analysis
RedHill Biopharma disclosed 86 risk factors in its most recent earnings report. RedHill Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
RedHill Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $3.96M | -0.58 | -85.94% | ― | 26.83% | 48.18% | |
46 Neutral | $1.84M | -0.50 | 2.66% | ― | -22.44% | -100.02% | |
45 Neutral | $29.01M | -0.87 | ― | ― | -7.07% | 75.39% | |
44 Neutral | $5.35M | -0.28 | ― | ― | ― | ― | |
43 Neutral | $1.38M | -0.04 | ― | ― | ― | ― | |
| ― | $2.66M | -0.21 | -9999.00% | ― | ― | 92.53% |
* Healthcare Sector Average
RDHL
RedHill Biopharma
1.03
-1.02
-49.76%
CPHI
China Pharma Holdings
0.72
-0.91
-56.07%
SNOA
Sonoma Pharmaceuticals
1.14
-2.18
-65.66%
PRFX
PainReform
1.59
-8.26
-83.86%
UPC
Universe Pharmaceuticals
3.27
-0.84
-20.44%
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
0.45
-4.37
-90.58%
RedHill Biopharma Corporate Events
RedHill Biopharma Moves to Advance Opaganib as Oral Antiviral Option for Current Ebola Outbreak
Jun 2, 2026
On June 2, 2026, RedHill Biopharma said it is pursuing collaborations to advance clinical development of its oral investigational drug opaganib against Ebola virus disease, especially the current outbreak of the rare Bundibugyo ebolavirus subtype....
RedHill Biopharma Expands At-The-Market ADS Offering to Boost Capital Flexibility
May 27, 2026
On May 7, 2026, RedHill Biopharma Ltd. filed a prospectus supplement to increase the maximum aggregate amount of American Depositary Shares that can be issued under its at-the-market equity offering program with H.C. Wainwright Co. The ADSs, each...
RedHill Biopharma Reports Promising MAP-Killing Data for Next-Generation Crohn’s Candidate RHB-204
Apr 30, 2026
On April 30, 2026, RedHill Biopharma reported new in vitro data showing that its next-generation oral candidate RHB-204 achieved Mycobacterium avium subspecies paratuberculosis (MAP) killing efficacy comparable to its predecessor RHB-104, in both ...
RedHill Biopharma Reshapes Talicia Franchise and Strengthens Balance Sheet in 2025 Results
Apr 27, 2026
RedHill Biopharma on April 27, 2026 reported its full-year 2025 results, highlighting a transformative year marked by the creation of Talicia Holdings Inc. and a U.S. co-commercialization deal with Cumberland Pharmaceuticals, which took a 30% stak...
RedHill Biopharma Showcases New Opaganib Preclinical Data in Neuroblastoma and Triple-Negative Breast Cancer at AACR 2026
Apr 22, 2026
On April 22, 2026, RedHill Biopharma reported new independently generated preclinical data presented at the 2026 American Association for Cancer Research meeting, showing its investigational drug opaganib may enhance the efficacy of existing treat...
RedHill Biopharma Receives Nasdaq Minimum Bid Price Deficiency Notice
Apr 14, 2026
RedHill Biopharma disclosed that on April 8, 2026 it received a notice from Nasdaq stating its American Depositary Shares had closed below the $1.00 minimum bid price requirement for continued listing for 30 consecutive business days between Febru...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.